Anti-inflammatory cells, like Tregs and M2-like macrophages, were upregulated in AML patients, while the expression of activated CD4+ T cells was significantly downregulated, leading to changes in the immune landscape, which aligns with prior research (Corradi et al., 2022; Weinhauser et al., 2023; Guo et al., 2021). This evidence concerns the gene CD4 and acute myeloid leukemia.